Abstract
Background: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. Objectives: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. Materials and methods: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled. Treatment was terminated by emptying of the radioimmunoconjugate from the bladder 120 min after instillation. Efficacy was evaluated via endoscopy and histology 6 weeks after instillation. Results: All patients showed excellent toleration of the treatment without any side effects. Treatment resulted in complete eradication of tumor cells in 3 patients and persistent tumor detection in the other 6 patients. Conclusions: Intravesical instillation of Bi-213-anti-EGFR-mAb is a promising therapeutic option for treatment of in situ bladder cancer after BCG failure for patients who wish to preserve the bladder.
Titel in Übersetzung | Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure |
---|---|
Originalsprache | Deutsch |
Seiten (von - bis) | 40-43 |
Seitenumfang | 4 |
Fachzeitschrift | Urologe - Ausgabe A |
Jahrgang | 56 |
Ausgabenummer | 1 |
DOIs | |
Publikationsstatus | Veröffentlicht - 1 Jan. 2017 |
Extern publiziert | Ja |
Schlagwörter
- Cystectomy, radical
- Instillation, bladder
- Radioimmunotherapy
- Resection, transurethral
- Tumor recurrence